tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Apogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory Challenges
PremiumCompany AnnouncementsApogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory Challenges
2M ago
Apogee Therapeutics Reports Promising Trial Results and Strong Cash Position
Premium
Company Announcements
Apogee Therapeutics Reports Promising Trial Results and Strong Cash Position
2M ago
Apogee Therapeutics reports Q2 net loss ($66.1M) vs ($33.816M) last year
Premium
The Fly
Apogee Therapeutics reports Q2 net loss ($66.1M) vs ($33.816M) last year
2M ago
Promising Phase II Results for Apogee Therapeutics’ APG777 Drive Buy Rating and $89 Price Target
PremiumRatingsPromising Phase II Results for Apogee Therapeutics’ APG777 Drive Buy Rating and $89 Price Target
3M ago
Promising Potential of Apogee Therapeutics’ APG777 in Atopic Dermatitis Market Drives Buy Rating and Increased Price Target
Premium
Ratings
Promising Potential of Apogee Therapeutics’ APG777 in Atopic Dermatitis Market Drives Buy Rating and Increased Price Target
3M ago
Apogee Therapeutics: Promising Phase 2 Results and Future Growth Potential Justify Buy Rating
Premium
Ratings
Apogee Therapeutics: Promising Phase 2 Results and Future Growth Potential Justify Buy Rating
3M ago
Video: Tesla dips as William Blair downgrades, Musk promises new political party
PremiumThe FlyVideo: Tesla dips as William Blair downgrades, Musk promises new political party
3M ago
Apogee Therapeutics Reports Positive Phase 2 Trial Results
Premium
Company Announcements
Apogee Therapeutics Reports Positive Phase 2 Trial Results
3M ago
Apogee Therapeutics says APEX Part A met all primary, secondary endpoints
Premium
The Fly
Apogee Therapeutics says APEX Part A met all primary, secondary endpoints
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100